Sentences with phrase «reported preclinical»

The attendees agreed on a common set of Principles and Guidelines in Reporting Preclinical Research (www.nih.gov/about/reporting-preclinical-research.htm) that list proposed journal policies and author reporting requirements to promote transparency and reproducibility.

The researchers are reporting preclinical findings for a potential two - treatment strategy to block multiple mechanisms of cancer cell metabolism in pancreatic cancer at the American Association for Cancer Research Annual...

Not exact matches

Differences between animal and human liver activity often result in under - reported human toxicities in preclinical animal testing of drug compounds.

«Improving the design, conduct, and reporting of preclinical research is of the utmost priority if we are to move ahead, with all due haste, in the development of novel treatments across a range of diseases.»

As reported in Nature this week, preclinical tests showed promising immune responses in both mice and monkeys.

The study can be seen in Cell Reports and provides an explanation for why the clinical trials for Alzheimer's disease drugs have failed and gives new light on the discord between preclinical and clinical findings.

In a paper published in Advanced Functional Materials, the research team reports on the new material's key properties, many of which can be finely tuned, and on the results of using the material in preclinical models of wound healing.

► In another Tuesday ScienceInsider, Jocelyn Kaiser reported that «[a] n eye - popping $ 28 billion is spent in the United States each year on preclinical research that can't be reproduced by other researchers.»

This human data follows extremely promising preclinical data (much of which was reported at the previous year's San Antonio Breast Cancer Symposium) supporting the androgen receptor as a target in breast cancer.

«We report much higher therapeutic efficacy in preclinical brain tumor models using the combination of both therapies, leading to an increase in median survival,» Lowenstein says.

The study, which lays the foundation for future preclinical work, appears June 14 in Stem Cell Reports, a publication of the International Society for Stem Cell Researchers.

A few years ago, two pharmaceutical companies reported that they could not replicate the vast majority of academic findings in preclinical experiments.

Syndax Pharmaceuticals, Inc. («Syndax,» the «Company» or «we»)(Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX - 6352 in multiple cancer indications, in collaboration with The Wistar Institute and Indiana University Melvin and Bren Simon Cancer Center, today announced the publication of a preclinical report demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (MDSCs).

Fisher and his colleagues are pioneering this approach and have already reported success in preclinical experiments utilizing UTMD technology and mda - 7 / IL - 24 gene therapy in prostate and colorectal cancer models.

These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, uncertainty regarding potential future deterioration in the market for auction rate securities which could result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

M1: Passive transfer studies in preclinical model performed; Report on protection by passive therapy with human immune IgG

In addition to AFFiRiS and Prothena, BioArctic Neuroscience AB continues to report earlier - stage but promising preclinical results with their lead candidate PD0805, a mAB targeting AS protofibrils.

Previous studies from the laboratory of Daniel B. F. Saris (University Medical Center Utrecht, The Netherlands) reported that a novel stem cell combination represented a safe and efficient means to repair cartilage in preclinical [1] and early clinical studies [2].

Previously we reported the development of liposome - based vaccines and their efficacy and safety in preclinical mouse models for tauopathy.

BACKGROUND Despite widely reported clinical and preclinical studies of rapid antidepressant actions of glutamate N - methyl - D - aspartate (NMDA) receptor antagonists, there has been very little work

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the outcome of the review of the continued listing of our common stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

Preclinical studies of vaccine candidates have typically shown post-infection virologic control, but protection against acquisition of infection has previously only been reported using less rigorous viral challenges.

Here we report the development and preclinical characterization of a novel CD123 - targeting ADC, IMGN632, which utilizes a highly potent DNA - alkylating payload, resulting in an ADC with robust preclinical activity in multiple models of AML.

Consistent with preclinical studies, adults with depression have been reported to have multiple alterations of the hypothalamic pituitary adrenal axis (9), increased cerebrospinal fluid corticotropin - releasing hormone (10), elevated cerebrospinal fluid norepinephrine concentration (11), decreased cortical γ - aminobutyric acid measured in vivo using proton magnetic resonance spectroscopy (12), and multiple indicators of altered serotonin (5 - HT) functioning (13), including reduced serotonin transporter (5 - HTT) availability as evidenced by reduced [123I] β - CIT spect binding (14).

Because many of the biological alterations associated with early stress in preclinical studies have been reported in adults with depression, it has been hypothesized that the neurobiological changes associated with adverse early experiences may confer a vulnerability for the development of depression (6, 8).